UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
(Address of registrant’s principal executive office) | (Zip code) |
(
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Title of each class | Trading symbol(s) | Name
of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 17, 2022, David Epstein resigned from his position as a member of the Board and any committees thereof, effective immediately. Mr. Epstein’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 17, 2022 | RUBIUS THERAPEUTICS, INC. | |
By: | /s/ Pablo J. Cagnoni | |
Pablo J. Cagnoni | ||
Chief Executive Officer |
Cover |
Oct. 17, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Oct. 17, 2022 |
Entity File Number | 001-38586 |
Entity Registrant Name | RUBIUS THERAPEUTICS, INC. |
Entity Central Index Key | 0001709401 |
Entity Tax Identification Number | 46-2688109 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 399 Binney Street |
Entity Address, Address Line Two | Suite 300 |
Entity Address, City or Town | Cambridge |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02139 |
City Area Code | 617 |
Local Phone Number | 679-9600 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | RUBY |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
&UL4$L! A0#
M% @ IX!15=+?/JUC! (1$ !@ ("!#0@ 'AL+W=O
M
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